Capecitabine plus Irinotecan for Advanced Gastric Cancer
Author Information
Author(s): Baek J H, Kim J G, Jeon S B, Chae Y S, Kim D H, Sohn S K, Lee K B, Choi Y J, Shin H J, Chung J S, Cho G J, Jung H Y, Yu W
Primary Institution: Kyungpook National University Hospital
Hypothesis
The study aims to evaluate the efficacy and safety of a combination regimen of capecitabine plus irinotecan in patients with advanced gastric cancer.
Conclusion
The combination of capecitabine and irinotecan was found to be well tolerated and effective in patients with advanced gastric cancer.
Supporting Evidence
- Three complete responses and 16 partial responses were confirmed, giving an overall response rate of 46.3%.
- The median time to progression was 5.1 months and overall survival was 8.6 months.
- Grade 3/4 neutropenia occurred in four patients, indicating some serious side effects.
Takeaway
Doctors tested a new medicine combination to help people with a serious stomach cancer, and it worked pretty well without making them too sick.
Methodology
Patients received oral capecitabine and intravenous irinotecan in a specific schedule, and their responses were measured over time.
Potential Biases
Potential selection bias due to the study being conducted at specific centers.
Limitations
The study had a small sample size and was limited to patients from two centers.
Participant Demographics
Median age was 59 years, with 30 men and 11 women; most had a good performance status.
Statistical Information
P-Value
0.046
Confidence Interval
95% CI: 30.4–62.3%
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website